Sarepta Therapeutics (SRPT) EBIT: 2012-2025
Historic EBIT for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to -$300.4 million.
- Sarepta Therapeutics' EBIT fell 42751.07% to -$300.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$117.2 million, marking a year-over-year decrease of 408.55%. This contributed to the annual value of $218.1 million for FY2024, which is 181.43% up from last year.
- According to the latest figures from Q2 2025, Sarepta Therapeutics' EBIT is -$300.4 million, which was down 285.79% from $161.7 million recorded in Q4 2024.
- Sarepta Therapeutics' 5-year EBIT high stood at $161.7 million for Q4 2024, and its period low was -$300.4 million during Q2 2025.
- In the last 3 years, Sarepta Therapeutics' EBIT had a median value of -$701,000 in 2024 and averaged -$38.9 million.
- In the last 5 years, Sarepta Therapeutics' EBIT skyrocketed by 556.57% in 2024 and then tumbled by 42,751.07% in 2025.
- Sarepta Therapeutics' EBIT (Quarterly) stood at -$105.8 million in 2021, then fell by 0.96% to -$106.8 million in 2022, then soared by 123.05% to $24.6 million in 2023, then skyrocketed by 556.57% to $161.7 million in 2024, then crashed by 42,751.07% to -$300.4 million in 2025.
- Its last three reported values are -$300.4 million in Q2 2025, $161.7 million for Q4 2024, and $22.2 million during Q3 2024.